212 related articles for article (PubMed ID: 18669871)
1. Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1.
Ding C; Wang L; Marroquin J; Yan J
Blood; 2008 Oct; 112(7):2817-25. PubMed ID: 18669871
[TBL] [Abstract][Full Text] [Related]
2. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.
Soares MM; Mehta V; Finn OJ
J Immunol; 2001 Jun; 166(11):6555-63. PubMed ID: 11359807
[TBL] [Abstract][Full Text] [Related]
3. Targeting of antigens to B lymphocytes via CD19 as a means for tumor vaccine development.
Ma Y; Xiang D; Sun J; Ding C; Liu M; Hu X; Li G; Kloecker G; Zhang HG; Yan J
J Immunol; 2013 Jun; 190(11):5588-99. PubMed ID: 23630363
[TBL] [Abstract][Full Text] [Related]
4. Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(D,L-lactic-co-glycolic acid) nanoparticles.
Hamdy S; Elamanchili P; Alshamsan A; Molavi O; Satou T; Samuel J
J Biomed Mater Res A; 2007 Jun; 81(3):652-62. PubMed ID: 17187395
[TBL] [Abstract][Full Text] [Related]
5. Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response.
Madsen CB; Petersen C; Lavrsen K; Harndahl M; Buus S; Clausen H; Pedersen AE; Wandall HH
PLoS One; 2012; 7(11):e50139. PubMed ID: 23189185
[TBL] [Abstract][Full Text] [Related]
6. Whole protein and defined CD8(+) and CD4(+) peptides linked to penetratin targets both MHC class I and II antigen presentation pathways.
Pouniotis DS; Esparon S; Apostolopoulos V; Pietersz GA
Immunol Cell Biol; 2011 Nov; 89(8):904-13. PubMed ID: 21383765
[TBL] [Abstract][Full Text] [Related]
7. Innate profiles of cytokines implicated on oral tolerance correlate with low- or high-suppression of humoral response.
Silva MF; Kamphorst AO; Hayashi EA; Bellio M; Carvalho CR; Faria AM; Sabino KC; Coelho MG; Nobrega A; Tavares D; Silva AC
Immunology; 2010 Jul; 130(3):447-57. PubMed ID: 20331474
[TBL] [Abstract][Full Text] [Related]
8. Induction of homologous rather than heterologous antigen-specific CD4 T cell responses is critical for functional CD8 T cell responses in mice transgenic for a foreign antigen.
Sabarth N; Chamberlain L; Brett S; Tite J; Craigen J
J Immunol; 2010 Oct; 185(8):4590-601. PubMed ID: 20861346
[TBL] [Abstract][Full Text] [Related]
9. Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.
Ye Z; Ahmed KA; Hao S; Zhang X; Xie Y; Munegowda MA; Meng Q; Chibbar R; Xiang J
Autoimmunity; 2008 Nov; 41(7):501-11. PubMed ID: 18855194
[TBL] [Abstract][Full Text] [Related]
10. Anti-T-cell humoral and cellular responses in healthy BALB/c mice following immunization with ovalbumin or ovalbumin-specific T cells.
Zhang XY; Liu XG; Wang W; Wang WC; Gao XM
Immunology; 2003 Apr; 108(4):465-73. PubMed ID: 12667208
[TBL] [Abstract][Full Text] [Related]
11. Augmenting Vaccine Immunogenicity through the Use of Natural Human Anti-rhamnose Antibodies.
Hossain MK; Vartak A; Karmakar P; Sucheck SJ; Wall KA
ACS Chem Biol; 2018 Aug; 13(8):2130-2142. PubMed ID: 29916701
[TBL] [Abstract][Full Text] [Related]
12. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine.
Karan D; Krieg AM; Lubaroff DM
Int J Cancer; 2007 Oct; 121(7):1520-8. PubMed ID: 17565748
[TBL] [Abstract][Full Text] [Related]
13. Oral antigen inhibits priming of CD8+ CTL, CD4+ T cells, and antibody responses while activating CD8+ suppressor T cells.
Ke Y; Kapp JA
J Immunol; 1996 Feb; 156(3):916-21. PubMed ID: 8558017
[TBL] [Abstract][Full Text] [Related]
14. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.
Rowe HM; Lopes L; Ikeda Y; Bailey R; Barde I; Zenke M; Chain BM; Collins MK
Mol Ther; 2006 Feb; 13(2):310-9. PubMed ID: 16275163
[TBL] [Abstract][Full Text] [Related]
15. Efficient priming of CD4+ and CD8+ T cells by DNA vaccination depends on appropriate targeting of sufficient levels of immunologically relevant antigen to appropriate processing pathways.
Rush C; Mitchell T; Garside P
J Immunol; 2002 Nov; 169(9):4951-60. PubMed ID: 12391208
[TBL] [Abstract][Full Text] [Related]
16. CD8 blockade promotes antigen responsiveness to nontolerizing antigen in tolerant mice by inhibiting apoptosis of CD4+ T cells.
Wang Z; Davies JD
J Immunol; 2007 May; 178(10):6148-57. PubMed ID: 17475841
[TBL] [Abstract][Full Text] [Related]
17. In vivo behavior of peptide-specific T cells during mucosal tolerance induction: antigen introduced through the mucosa of the conjunctiva elicits prolonged antigen-specific T cell priming followed by anergy.
Egan RM; Yorkey C; Black R; Loh WK; Stevens JL; Storozynsky E; Lord EM; Frelinger JG; Woodward JG
J Immunol; 2000 May; 164(9):4543-50. PubMed ID: 10779755
[TBL] [Abstract][Full Text] [Related]
18. A Rapid-Response Humoral Vaccine Platform Exploiting Pre-Existing Non-Cognate Populations of Anti-Vaccine or Anti-Viral CD4+ T Helper Cells to Confirm B Cell Activation.
Hills T; Jakeman PG; Carlisle RC; Klenerman P; Seymour LW; Cawood R
PLoS One; 2016; 11(11):e0166383. PubMed ID: 27861512
[TBL] [Abstract][Full Text] [Related]
19. Selective expansion of merocytic dendritic cells and CD8DCs confers anti-tumour effect of Fms-like tyrosine kinase 3-ligand treatment in vivo.
Hennies CM; Reboulet RA; Garcia Z; Nierkens S; Wolkers MC; Janssen EM
Clin Exp Immunol; 2011 Mar; 163(3):381-91. PubMed ID: 21235535
[TBL] [Abstract][Full Text] [Related]
20. Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy.
Snook AE; Magee MS; Schulz S; Waldman SA
Eur J Immunol; 2014 Jul; 44(7):1956-66. PubMed ID: 24771148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
